Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SymBio to Start Clinical
May 22, 2006
- JPMA
May 22, 2006
- Kissei, Daiichi Start Comarketing
May 22, 2006
- Takeda Aims at \2 Trillion
May 22, 2006
- More Companies Introducing
May 22, 2006
- Pfizer Japan's MRs Remain
May 22, 2006
- BUSINESS NEWS IN BRIEF
May 22, 2006
- Plan of Action for Industry Vision Reviewed
May 22, 2006
- Japan Pediatric Society's Scientific Meeting
May 22, 2006
- Drug Discovery & Development Summit Japan
May 15, 2006
- COMMENTARY 3 articles
May 15, 2006
- LDP to Take Initiative to Promote
May 15, 2006
- TeGenero Incident Victims
May 15, 2006
- Banyu to Focus on Basic Research,
May 15, 2006
- R&D NEWS IN BRIEF
May 15, 2006
- New Drug Improves Quality of Sleep: Rohto
May 15, 2006
- Abbott Acquires Guidant Vascular Business
May 15, 2006
- Astellas Licenses Anemia
May 15, 2006
- Morimoto-Iyaku Establishes
May 15, 2006
- Novartis Pharma Integrates Marketing Systems
May 15, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…